Teddy V. - Pharma8k's (Page 2)

BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients

12 Dec 2025 SEC Filing 8-K FDA $BCRX

BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients

BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric hereditary angioedema patients aged 2 to <12 years.

Merus N.V. (MRUS) Acquired by Genmab in $6.9 Billion Deal, Announces Leadership Changes

12 Dec 2025 SEC Filing 8-K M&A $MRUS

Merus N.V. (MRUS) Acquired by Genmab in $6.9 Billion Deal, Announces Leadership Changes

Merus N.V. (MRUS) completed its acquisition by Genmab A/S for $6.9 billion, resulting in a change of control and new executive appointments.

BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients Aged 2-12

12 Dec 2025 SEC Filing 8-K FDA $BCRX

BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients Aged 2-12

BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years, expanding its market reach.

Merus N.V. (MRUS) Acquired by Genmab for $6.9 Billion, Completes Change in Control

12 Dec 2025 SEC Filing 8-K M&A $MRUS

Merus N.V. (MRUS) Acquired by Genmab for $6.9 Billion, Completes Change in Control

Merus N.V. (MRUS) completed its acquisition by Genmab A/S for approximately $6.9 billion, resulting in a change in control and leadership changes.

Rafael Holdings (RFL) Reports Q1 Loss of $9.8M as Phase 3 NPC Trial Continues

12 Dec 2025 SEC Filing 8-K $RFL

Rafael Holdings (RFL) Reports Q1 Loss of $9.8M as Phase 3 NPC Trial Continues

Rafael Holdings (RFL) filed an 8-K on Dec 11, 2025, reporting a Q1 net loss of $9.8M and positive DMC review for its Phase 3 NPC drug trial.